Concentration of an epidermal growth factor in blood serum of males during topical treatment of psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 12, Issue 1, 1999, Pages 1-5

  Pietrzak, A ^a   Miturski, R ^a   Krasowska, D ^a   Postawski, K ^a   Lecewicz Torun, B ^a  

^a Department of Dermatology ^*  (Poland)

Author keywords

Dithranol; Male; Psoriasis; Serum epidermal growth factor

Indexed keywords

EPIDERMAL GROWTH FACTOR;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; HUMAN; MALE; PRIORITY JOURNAL; PSORIASIS; STATISTICAL ANALYSIS;

EID: 0033002380     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0926-9959(98)00115-9     Document Type: Article

References (16)

1. Higashiyama M, Hashimoto K, Matsumoto K,Yoshikawa K. Differential expression of transforming growth factor- α (TGF-alpha) and EGF receptor in transitional area of psoriatic epidermis. J Dermatol Sci 1994;7:45–53.
2. Gentleman S, Martensen T, Digiovannak JJ, Chader GJ. Protein tyrosine kinase and protein phosphotyrosine phosphatase in normal and psoriatic skin. Biochim Biophys Acta 1984;798:53–59.
3. Amagai M, Ozawa S, Ueda M, et al. Distribution of EGF receptor expressing and DNA replicating epidermal cells in psoriasis vulgaris and Bowen's disease. Br J Dermatol 1988;119:661–668.
4. Nanney LB, Stoscheck CM, Magid M, King LE, Jr. Altered [125 I] epidermal growth factor binding and receptor distribution in psoriasis. J Invest Dermatol 1986;86:260–265.
5. Kulke R, Bartels J, Schluter C, Christophers E. Overexpression of the EGF-receptor cDNA in foreskin derived keratinocytes causes epidermal hyperplasia in raft culture. In: Book of Abstracts, 26th Annual Meeting of European Society for Dermatological Research Amsterdam. Oxford: Blackwell Science,1996;161:85.
6. Miturski R, Pietrzak A, Krasowska D, Lecewicz-Toruń B. The presence of epidermal growth factor receptors (EGF-r) and tyrosine kinase activity stimulated by EGF(EGF-TK) in psoriatic epidermis. Preliminary findings. J Eur Acad Dermatol Venereol 1996;Suppl. 2:191.
7. De Pita O, Ruffelli M, Cadoni S, et al. Psoriasis: comparison of immunological markers in patients with acute and remission phase. J Dermatol Sci 1996;13:118–124.
8. Venier A, De Simone C, Forni A, et al. Treatment of severe psoriasis with somatostatin: four years of experience. Arch Dermatol Res 1988;280:51–54.
9. Dailey GE, Kraus JW, Orth DN. Homologous radioimmunoassay for human epidermal growth factor (urogastrone). J Clin Endocrinol Metab 1978;46:929–936.
10. Esgleyes-Ribot T, Chandraratna R, Lew-Kaya DA, et al. Response of psoriasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol 1994;30:581–590.
11. Gottlieb AB, Khandke L, Krane JF, et al. Anthralin decreases keratinocyte TGF-alpha expression and EGF- receptor binding in vitro. J Invest Dermatol 1992;98:680–685.
12. Kemeny L, Michel G, Arenberg P, Ruzicka T. Down regulation of epidermal growth factor receptors by dithranol. Acta Derm Venereol Stockh 1993;73:37–40.
13. Nanney LB, Yates RA, King LE Jr. Modulation of epidermal growth factor receptors in psoriatic lesions during treatment with topical EGF. J Invest Dermatol 1992;98:296–301.
14. Ockenfelds HM, Nussbaum G, Schulterwolter T, et al. Cyclosporin A, FK 506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes. J Arch Dermatol Res 1995;287:304–309.
15. Pietrzak A, Lecewicz-Toruń B, Chodorowska G, et al. Epidermal growth factor concentration in the sera of male psoriatic patients. Acta Derm Venereol (Stockh) 1997;77:489–490.
16. Oka T, Orth DN. Human plasma EGF/ β -urogastrone associated with blood platelets. J Clin Invest 1983;72:249–259.